Acorda Therapeutics, Inc. · Hawthorne, NY United States · (NASDAQ (GM): ACOR)
Company Description
More Companies in: Hawthorne, New York
More Companies in These Related Industries: Biologics Mfg, Pharmaceutical Preparation Mfg
View Acorda Therapeutics, Inc. Locations On A US Map
This link will open in a new window
This link will open in a new window Acorda Therapeutics hopes its products really get on your nerves. The company is developing therapeutics that aim to restore neurological function for patients with spinal cord injury and other central nervous system disorders. The company markets and sells muscle relaxant Zanaflex in the US. Its lead drug development candidate is Fampridine-SR, which enhances conduction in the myelin layer of nerves damaged by blunt trauma or from multiple sclerosis (MS). The drug uses a sustained-release delivery system developed by and licensed from Elan Corporation . Acorda's other drug candidates include potential therapies for MS, brain damage, and spinal cord injuries. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Acorda Therapeutics, Inc. Reports
No subscription, no problem.
Download presentation-ready reports for this company now.
Download presentation-ready reports for this company now.
From company profiles to the competitive landscape, Hoover’s offers immediate access to individual reports.
Key Acorda Therapeutics, Inc. Financials
| Company Type | Public - NASDAQ (GM): ACOR Headquarters |
| Fiscal Year-End | December |
| 2009 Employees | 249 |
Acorda Therapeutics, Inc. Executives
27 executives listed for Acorda Therapeutics, Inc.'s Hawthorne, NY location.
| Title | Name & Bio | Contact |
| President CEO, and Director | Ron Cohen | |
| CFO | David Lawrence | |
| Chief Scientific Officer | Andrew Blight |
Competition
Competitive Landscape for Acorda Therapeutics, Inc.
Demand often depends on the income of consumers or the profitability of business customers, because many technology products and services are expensive. The profitability of individual companies is driven by their ability to develop and market new products. Large companies often have advantages in access to capital and marketing. Small companies can compete successfully if they have expertise in a particular field of knowledge. The industry is capital-intensive: average annual revenue per worker is nearly $300,000. To read the full description, subscribe now.Top Acorda Therapeutics, Inc. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!